Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Structure

• Publication date

  2014-12-02

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.str.2014.09.019PMID 25465127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures.

  2014cited by this paper
• DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors

  2014cited by this paper
• Targeted inhibition of the FGF19‐FGFR4 pathway in hepatocellular carcinoma; translational safety considerations

  2014cited by this paper
• Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.

  2014cited by this paper
• Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

  2014cited by this paper
• Structural analysis of the human fibroblast growth factor receptor 4 kinase.

  2014cited by this paper
• Decision making in xia2

  2013cited by this paper
• Cracking the molecular origin of intrinsic tyrosine kinase activity through analysis of pathogenic gain-of-function mutations.

  2013cited by this paper
• Exploring mechanisms of FGF signalling through the lens of structural biology

  2013cited by this paper
• Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation.

  2013cited by this paper
• Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

  2013cited by this paper
• The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

  2013cited by this paper
• Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

  2012cited by this paper
• Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

  2012influential reference
• Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer

  2012cited by this paper
• Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives

  2012cited by this paper
• Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.

  2012cited by this paper
• Structural approaches to obtain kinase selectivity.

  2012cited by this paper
• AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

  2012influential reference
• Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys.

  2012cited by this paper
• Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

  2011cited by this paper
• Overview of the CCP4 suite and current developments

  2011cited by this paper
• Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

  2011influential reference
• Targeting mutant fibroblast growth factor receptors in cancer.

  2011cited by this paper
• Data processing and analysis with the autoPROC toolbox

  2011cited by this paper
• REFMAC5 for the refinement of macromolecular crystal structures

  2011cited by this paper
• Presenting your structures: the CCP4mg molecular-graphics software

  2011cited by this paper
• Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression

  2011cited by this paper
• The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

  2010cited by this paper
• A structure-guided approach to creating covalent FGFR inhibitors.

  2010cited by this paper
• Features and development of Coot

  2010cited by this paper
• Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.

  2010cited by this paper
• Fibroblast growth factor signalling: from development to cancer

  2010cited by this paper
• EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis.

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression

  2009cited by this paper
• Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

  2009cited by this paper
• FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation

  2009cited by this paper
• Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

  2009cited by this paper
• MolProbity: all-atom structure validation for macromolecular crystallography

  2009cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Activation of tyrosine kinases by mutation of the gatekeeper threonine

  2008cited by this paper
• Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models

  2008cited by this paper
• Liver-specific Activities of FGF19 Require Klotho beta*

  2007cited by this paper
• Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.

  2007cited by this paper
• Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.

  2007cited by this paper
• A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

  2007influential reference
• Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21*

  2007cited by this paper
• The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• Phaser crystallographic software

  2007cited by this paper
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• Thermodynamics of binding interactions in the rational drug design process

  2007cited by this paper
• FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Scaling and assessment of data quality.

  2006cited by this paper
• FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

  2006cited by this paper
• Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism

  2006cited by this paper
• Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2006cited by this paper
• FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.

  2005cited by this paper
• Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.

  2005cited by this paper
• Somatic mutations of the protein kinase gene family in human lung cancer.

  2005cited by this paper
• Retrieval of Crystallographically-Derived Molecular Geometry Information

  2004cited by this paper
• The Cambridge Structural Database: a quarter of a million crystal structures and rising.

  2002cited by this paper
• Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.

  2002cited by this paper
• Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.

  2001cited by this paper
• Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

  2000cited by this paper
• The finer things in X-ray diffraction data collection.

  1999cited by this paper
• A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src.

  1998cited by this paper
• FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung.

  1998cited by this paper
• Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.

  1996influential reference
• Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures

  1994cited by this paper
• AMoRe: an automated package for molecular replacement

  1994cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• Electronic Reprint Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions

  year unknowncited by this paper

• Ligand-based graph neural network, molecular dynamics and biological evaluation for identification of potential FGFR1 kinase inhibitors.

  2026cites this paper
• Development of a series of novel potent and selective irreversible covalent FGFR4 inhibitors with a mix-and-match strategy.

  2025cites this paper
• Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection

  2025influential citation
• Structural basis for MEKK2 dimerization and substrate recognition

  2025cites this paper
• Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma

  2025cites this paper
• Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges.

  2025cites this paper
• Discovery of a 1H-Pyrazol-3-Amine Derivative as a Novel, Selective, and Orally Available RIPK1 Inhibitor for the Treatment of Inflammatory Disease.

  2025cites this paper
• Discovery of INCB126503 as a Potent and Selective FGFR2/3 Inhibitor.

  2025cites this paper
• Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies

  2024cites this paper
• Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance

  2024cites this paper
• Computational Biophysical Characterization of the Effect of Gatekeeper Mutations on the Binding of Ponatinib to the FGFR Kinase.

  2024cites this paper
• Macrophage-derived FGFR1 drives atherosclerosis through PLCγ-mediated activation of NF-κB inflammatory signaling pathway.

  2024cites this paper
• Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion

  2024cites this paper
• Imidazole-Derived Alkyl and Aryl Ethers: Synthesis, Characterization, In Vitro Anticancer and Antioxidant Activities, Carbonic Anhydrase I–II Inhibition Properties, and In Silico Studies

  2024cites this paper
• Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.

  2024cites this paper
• A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

  2024cites this paper
• Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors

  2024cites this paper
• Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma.

  2024cites this paper
• Virtual Screening and Lead Optimization of Desmostachya bipinnata-Derived FGFR Inhibitors for Oral Squamous Cell Carcinoma Management

  2024cites this paper
• Benzimidazole–dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions

  2024cites this paper
• Developing New Peptides and Peptide–Drug Conjugates for Targeting the FGFR2 Receptor-Expressing Tumor Cells and 3D Spheroids

  2024cites this paper
• A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors.

  2024cites this paper
• Exploring the Impact of Protein Chain Selection in Binding Energy Calculations with DFT

  2024cites this paper
• Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.

  2024cites this paper
• Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents

  2024cites this paper
• Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.

  2023cites this paper
• From nature to cancer therapy: Evaluating the Streptomyces clavuligerus secondary metabolites for potential protein kinase inhibitors

  2023cites this paper
• Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.

  2023cites this paper
• Investigating the potential inhibitory effect of the megaphone (molecule) on nasopharyngeal cancer growth factor receptors

  2023cites this paper
• Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents.

  2023cites this paper
• Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling

  2023cites this paper
• Mechanisms Involved in the Therapeutic Effect of Cannabinoid Compounds on Gliomas: A Review with Experimental Approach.

  2023cites this paper
• Sanggenol B, a plant bioactive, as a safer alternative to tackle cancer by antagonising human FGFR

  2023cites this paper
• Discovery of a new potent oxindole multi-kinase inhibitor among a series of designed 3-alkenyl-oxindoles with ancillary carbonic anhydrase inhibitory activity as antiproliferative agents

  2023cites this paper
• Ponatinib: An update on its drug targets, therapeutic potential and safety.

  2023cites this paper
• Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis

  2023cites this paper
• Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach.

  2023cites this paper
• The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention

  2023cites this paper
• Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs

  2023influential citation
• Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.

  2023cites this paper
• Inhibition of Cancer Cell Proliferation and Bacterial Growth by Silver(I) Complexes Bearing a CH3-Substituted Thiadiazole-Based Thioamide

  2023cites this paper
• Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

  2022cites this paper
• Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.

  2022cites this paper
• Silver(I) complexes bearing heterocyclic thioamide ligands with NH2 and CF3 substituents: effect of ligand group substitution on antibacterial and anticancer properties.

  2022cites this paper
• Fibroblast growth factor receptor (FGFR) inhibitors as anticancer agents: 3D-QSAR, molecular docking and dynamics simulation studies of 1, 6-naphthyridines and pyridopyrimidines

  2022influential citation
• Molecular dynamics study of Quercetin families and its derivative compounds from Carica papaya leaf as breast cancer inhibitors

  2022cites this paper
• Structural study of ponatinib in inhibiting SRC kinase.

  2022cites this paper
• Deciphering the molecular mechanisms of selective non-covalency demonstrated differentially by 9-Allylnaphtho[1,8-ef]isoindole-7,8,10(9H)-trione (C11) against fibroblast growth factor receptors 1–4

  2022cites this paper
• Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011–2020): Current Status and Future Prospects

  2022cites this paper
• From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.

  2021cites this paper
• FGFR-TKI resistance in cancer: current status and perspectives

  2021cites this paper
• Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.

  2021cites this paper
• Exploring the endogenous potential of Hemidesmus indicus against breast cancer using in silico studies and quantification of 2-hydroxy-4-methoxy benzaldehyde through RP-HPLC

  2021cites this paper
• Ultrasound promoted synthesis of N-(substituted phenyl)-2-(7‑hydroxy-4-methyl-2H-chromen-2-ylidene)hydrazine-1-carboxamides as cytotoxic and antioxidant agents

  2021cites this paper
• Validation of ion mobility spectrometry ‐ mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase

  2021cites this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cites this paper
• Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates as FGFR1 inhibitors

  2021influential citation
• Design and development of a photoswitchable DFG-out kinase inhibitor.

  2021cites this paper
• From Fragment to Lead: A Structure-Guided Approach Towards a Selective FGFR2 Inhibitor

  2021cites this paper
• Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs

  2021cites this paper
• Receptor Tyrosine Kinases

  2021cites this paper
• Synthesis, anticancer evaluation and molecular docking of new benzothiazole scaffolds targeting FGFR-1.

  2021cites this paper
• Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma

  2021cites this paper
• FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential

  2021cites this paper
• Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multiangiokinase inhibitors targeting breast cancer

  2020cites this paper
• Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors

  2020cites this paper
• AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting In fl ammation: The Role of FGFR1 in Renal Tubular Epithelial Cells

  2020cites this paper
• Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules.

  2020cites this paper
• The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

  2020cites this paper
• Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.

  2020cites this paper
• Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer.

  2020cites this paper
• AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells

  2020cites this paper
• FGF19–FGFR4 Signaling in Hepatocellular Carcinoma

  2019cites this paper
• Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.

  2019cites this paper
• The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.

  2019cites this paper
• Design, synthesis and biological evaluation of novel 1H-1,2,4-triazole, benzothiazole and indazole-based derivatives as potent FGFR1 inhibitors viafragment-based virtual screening

  2019cites this paper
• Benzimidazoles: From Antiproliferative to Multitargeted Anticancer Agents

  2019cites this paper
• Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

  2019influential citation
• A patent review of FGFR4 selective inhibition in cancer (2007-2018)

  2019influential citation
• Making way for suppressing the FGF19/FGFR4 axis in cancer.

  2018cites this paper
• Cancer II

  2018cites this paper
• Ponatinib ( AP 24534 ) inhibits MEKK 3-KLF signaling and prevents formation and progression of cerebral cavernous malformations

  2018cites this paper
• Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study

  2018cites this paper
• FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis

  2018cites this paper
• Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting

  2018cites this paper
• Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia

  2018influential citation
• Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations

  2018cites this paper
• Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

  2018cites this paper
• Fibroblast growth factor receptors as treatment targets in clinical oncology

  2018cites this paper
• Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide-induced activation of hepatic stellate cells via suppressing inflammation

  2018cites this paper
• Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer

  2018cites this paper
• Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4

  2018cites this paper
• 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

  2018cites this paper
• Electron-vibration-vibration two-dimensional infrared spectroscopy as a structural probe of interactions in proteins and DNA

  2017cites this paper
• Inhibitors of the Fibroblast Growth Factor Receptor

  2017cites this paper
• Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.

  2017cites this paper
• An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.

  2017cites this paper
• Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

  2017cites this paper
• Mutation Detection of Fibroblast Growth Factor Receptor 3 for Infiltrative Hepatocellular Carcinoma by Whole-Exome Sequencing

  2017cites this paper
• E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

  2016cites this paper